A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: Study protocol

BMC Psychiatry

Volumn 15, Issue 1, 2015, Pages

  Lutgens, Danyael ^a,b   Iyer, Srividya ^a,b   Joober, Ridha ^a,b   Brown, Thomas G ^a,c   Norman, Ross ^d,e   Latimer, Eric ^c,f   Schmitz, Norbert ^c,f   Abdel Baki, Amal ^g   Abadi, Sherezad ^b   Malla, Ashok ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d WESTERN UNIVERSITY   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Case management; Critical period; First episode psychosis; Randomized controlled trial; Remission; Specialized early intervention; Treatment

Indexed keywords

ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG DEPENDENCE TREATMENT; EARLY INTERVENTION; FAMILY THERAPY; FOLLOW UP; HUMAN; MEDICATION COMPLIANCE; MENTAL HEALTH CARE; NEGATIVE SYNDROME; OUTCOME VARIABLE; POSITIVE SYNDROME; PSYCHOEDUCATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SAMPLE SIZE; SPECIALIZED EARLY INTERVENTION; ADOLESCENT; ADULT; CASE MANAGEMENT; CLINICAL PROTOCOL; FEMALE; MALE; MENTAL HEALTH SERVICE; PSYCHOTIC DISORDERS; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; CASE MANAGEMENT; CLINICAL PROTOCOLS; COGNITIVE THERAPY; EARLY MEDICAL INTERVENTION; FAMILY THERAPY; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; PSYCHOTIC DISORDERS; REMISSION INDUCTION; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84924912838     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-015-0404-2     Document Type: Article

References (61)

1. Organization WHO. The World health report: 2001: Mental health: new understanding, new hope. 2001
2. Rössler W, Joachim Salize H, Van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399-409.
3. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279.
4. Morgan V, McGrath J, Jablensky A, Badcock J, Waterreus A, Bush R, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med. 2013;44:2163-76.
5. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575-86.
6. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40:744-455.
7. Ösby U, Hammar N, Brandt L, Wicks S, Thinsz Z, Ekbom A, et al. Time trends in first admissions for schizophrenia and paranoid psychosis in Stockholm County. Sweden Schizophr Res. 2001;47:247-54.
8. Mueser KT, Bennett M, Kushner MG. Epidemiology of substance use disorders among persons with chronic mental illnesses. 1995
9. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19-28.
10. Goeree R, Farahati F, Burke N, Blackhouse G, O'Reilly D, Pyne J, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21:2017-28.
11. Malla A, Norman R, Schmitz N, Manchanda R, BÉChard-Evans L, Takhar J, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36:649-58.
12. Albert N, Bertelsen M, Thorup A, Petersen L, Jeppesen P, Le Quack P, et al. Predictors of recovery from psychosis: Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophr Res. 2011;125:257-66.
13. Austin SF, Mors O, Secher RG, Hjorthøj CR, Albert N, Bertelsen M, et al. Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up. Schizophr Res. 2013;150:163-8.
14. Birchwood M, Fiorillo A. The critical period for early intervention. Psychiatr Rehabil Skills. 2000;4:182-98.
15. Jeppesen P, Petersen L, Thorup A, Abel M-B, Øhlenschlaeger J, Christensen T, et al. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008;38:1157-66.
16. Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry. 2009;194:18-24.
17. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7:148-56.
18. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatr. 2004;161:473-9.
19. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-7.
20. Malla AK, Norman RM, Manchanda R, McLean TS, Harricharan R, Cortese L, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002;53:458-63.
21. Malla A, Norman R, Manchanda R, Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med. 2002;32:1109-19.
22. Malla AK, Norman RM, McLean TS, McIntosh E. Impact of phase-specific treatment of first episode of psychosis on Wisconsin Quality of Life Index (client version). Acta Psychiatr Scand. 2001;103:355-61.
23. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996;22:305.
24. Nordentoft M, Jeppesen P, Abel M, Kassow P, Petersen L, Thorup A, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis One-year follow-up of a randomised controlled trial. Br J Psychiatry. 2002;181:s98-s106.
25. Grawe R, Falloon I, Widen J, Skogvoll E. Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. Acta Psychiatr Scand. 2006;114:328-36.
26. Petersen L, Jeppesen P, Thorup A, Abel M-B, Øhlenschlæger J, Christensen TØ, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ. 2005;331:602.
27. Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329:1067.
28. Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction Randomised controlled trial. Br J Psychiatry. 2006;188:37-45.
29. Harvey P, Lepage M, Malla A. Benefits of enriched intervention compared with standard care for patients with recent-onset psychosis: a metaanalytic approach. Can J Psychiatry. 2007;52:464.
30. Linszen D, Dingemans P, Lenior M. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr Res. 2001;51:55-61.
31. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlæger J, Le Quach P, et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65:762-71.
32. Norman RM, Manchanda R, Malla AK, Windell D, Harricharan R, Northcott S. Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophr Res. 2011;129:111-5.
33. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Drugs. 1994;12:70-6.
34. Birchwood M, Spencer E, McGovern D. Schizophrenia: early warning signs. Adv Psychiatr Treat. 2000;6:93-101.
35. Malla AK, Norman R. Prodromal symptoms in schizophrenia. Br J Psychiatry. 1994;164:487-93.
36. McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, et al. Multiple-family groups and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry. 1995;52:679-87.
37. Zimmermann G, Favrod J, Trieu V, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res. 2005;77:1-9.
38. Turkington D, Dudley R, Warman DM, Beck AT. Cognitive-behavioral therapy for schizophrenia: a review. J Psychiatr Pract. 2004;10:5-16.
39. Miller WR. Motivational interviewing with problem drinkers. Behav Psychother. 1983;11:147-72.
40. Sobell LC, Sobell MB. Timeline follow-back. In: Measuring alcohol consumption. Totowa, NJ: Springer; 1992. p. 41-72.
41. Andreasen NC. Scale for the assessment of positive symptoms. Iowa City: University of Iowa; 1984.
42. Andreasen NC. Scale for the assessment of negative symptoms. Iowa City: University of Iowa; 1983.
43. Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261.
44. Ventura J, Green MF, Shaner A, Liberman RP. Training and quality assurance with the Brief Psychiatric Rating Scale:" the drift busters.". Int J Meth Psychiatr Res. 1993;3:221-44.
45. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-71.
46. Morosini P, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning. Acta Psychiatr Scand. 2000;101:323-9.
47. Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, Van Wijngaarden B. Client Socio-Demographic and Service Receipt Inventory-European Version: development of an instrument for international research EPSILON Study 5. Br J Psychiatry. 2000;177:s28-33.
48. Rosen A, Hadzi Pavlovic D, Parker G. The life skills profile. Schizophr Bull. 1989;15:325-37.
49. Park LC, Lipman RS. A comparison of patient dosage deviation reports with pill counts. Psychopharmacologia. 1964;6:299-302.
50. Cassidy CM, Rabinovitch M, Schmitz N, Joober R, Malla A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J Clin Psychopharmacol. 2010;30:64-7.
51. McGovern MP, Morrison DH. The chemical use, abuse, and dependence scale (CUAD): Rationale, reliability, and validity. J Subst Abuse Treat. 1992;9:27-38.
52. Horvath AO, Greenberg LS. Development and validation of the Working Alliance Inventory. J Couns Psychol. 1989;36:223.
53. Becker M, Diamond R, Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res. 1993;2:239-51.
54. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, et al. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992;6:209-23.
55. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatr. 2005;162:441-9.
56. Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2010;36:1001-8.
57. Jordan G, Lutgens D, Joober R, Lepage M, Iyer SN, Malla A. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014;75:e566-72.
58. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 1994;182:193-204.
59. Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38:1585-93.
60. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470.
61. Melau M, Jeppesen P, Thorup A, Bertelsen M, Petersen L, Gluud C, et al. The effect of five years versus two years of specialised assertive intervention for first episode psychosis-OPUS II: study protocol for a randomized controlled trial. Trials. 2011;12:72.